In-vivo study of brain tumor migration via electrospun nanofiber implants by Cho, Jae Sung
IN-VIVO STUDY OF BRAIN TUMOR MIGRATION VIA 



























In Partial Fulfillment 
of the Requirements for the Degree 
Bachelor of Science in the 











































 I wish to thank Martha Betancur, formerly a researcher at Neurological 
Biomaterials and Cancer Therapeutics Laboratory and currently a PhD candidate at the 
University of Georgia, for all the mentorship and guidance. I also wish to thank Dr. 
Balakrishna Pai for his unfailing kindness while allowing me this opportunity to explore 


















TABLE OF CONTENTS 
ACKNOWLEDGEMENTS iv 
LIST OF TABLES vi 
LIST OF Figures vii 
SUMMARY  ix 
CHAPTER 1: INTRODUCTION 1 
CHAPTER 2: Literature review 3 
CHAPTER 3: Materials and Methods 6 
CHAPTER 4: Results 7 
SeeDB Optical Clearing of Mice Brain 7 
Implant Results 10 
CHAPTER 5: Discussion 11 
Chapter 6: Conclusion 13 
Appendix A: MATERIALS AND METHODS 14 
PCL Nanofiber Protocol 14 
Implants Protocol 15 
Conduit Implant 15 
Silicone-tube Implant 15 
SeeDB Optical Clearing Protocol 16 





LIST OF TABLES 
Page 
Table A-1: SeeDB Solution Preparation 16 
  
 vii 
LIST OF FIGURES 
Page 
Figure 3-1: Implant Designs 6 
Figure 4-1: SeeDB cleared GBM tumor brain sample 7 
Figure 4 2: Brain implants prior to quantification 8 
Figure 4 3: Representative image of GBM migration 9 
Figure 4 4: Ratio of migrated GBM tumor to total tumor 10 
 viii 
LIST OF ABBREVIATIONS 
 
GBM  Glioblastoma Multiforme 
PCL  Polycaprolactone 
DCM  Dichloromethane 
PEG  Polyethylene glycol 
SeeDB  See Deep Brain optical clearing solution 
HFIP  Hexafuoro-2-propanol 











Glioblastoma multiforme (GBM), one of the deadliest forms of human brain 
cancer, migrates to different parts of the brain via the white matter tracts. This behavior is 
the basis for biomaterial research currently done to mimic white matter tracts so that 
GBM migration can be investigated .While there have been many in-vitro studies done on 
GBM migration with electrospun nanofiber films, only one in-vivo study has been done 
on GBM migration.  Encouraged by our findings on GBM cell  migration on aligned fiber 
films published in Nature Materials, we proposed  to make two new implant designs, the 
aligned conduit implant and the silicone tube implant and utilize these nanofiber films to 
investigate GBM cell migration from inside the brain to outside of the brain. It was found 
that the silicone tube implants had a design flaw that hindered GBM cell migration from 
the tumor. The aligned conduit implant facilitated GBM migration significantly with a p-
value of 2.01×10-4. Quantification of migration was done using a recently introduced 
SeeDB protocol, which greatly expedited analysis time. The results from in this 
investigation show that it is possible to design a brain implant that is able to remove 
GBM tumor non-invasively and will add to the advancement to biomedical technology in 






CHAPTER 1: INTRODUCTION 
Glioblastoma multiforme (GBM) accounts for nearly 50% of reported malignant 
gliomas, the most common type of primary brain tumor in adults. GBM  also accounts for 
approximately 70% of the 22,000 new cases of malignant primary brain tumors that are 
diagnosed in adults in the United States each year.[2] Despite advances in surgical 
techniques, neuroimaging, and adjuvant modalities such as chemotherapy and radiation, 
this class of cancer  remains resistant to treatment.[4] Median survival rate of patients 
diagnosed with GBM remains dismal (i.e., about 1 year) with tumor recurrence and 
progression inevitable in almost all cases.[2] Clinical observations suggest that these GBM 
tumors migrate as single cells, particularly along white matter tracts, despite the fact that 
white matter is an inhibitory substrate for neurite outgrowth and astrocyte migration.[4] 
The reasons for this phenomena is currently not yet fully understood.[5] However, this 
phenomenon has been a basis for many biomaterial models to mimic the white matter 
tract to induce migration of GBM and other malignant brain tumors.  
Since GBM tumors migrate along white matter tracts, there have been attempts to 
mimic white matter with electrospun nanofiber films.[10-12] As the anisotropic elongated 
structures and nanotopography accurately reflect the mechanical and structural cues 
present in the brain extracellular matrix (ECM) of the white matter tracts, electrospun 
nanofibers of polycaprolactone (PCL) with average diameters of 400 nm to 600 nm have 
been used to study GBM migration.[11, 12] It was also shown that aligned PCL nanofibers 
provide structural advantage for promoting cell migration.[12] The most promising model 
proposes to use core-shell electrospun nanofibers to mimic white matter tract topography 
to examine the migration of malignant brain tumors.[13]  
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However, despite the various attempts for mimicking white matter tract to 
examine migration of malignant brain tumors, there has only been one in-vivo study to 
confirm the prospect of an electrospun nanofiber implant for the migration of GBM. [14] 
This study showed that in a rat model, human GBM U87 cancer cells efficiently migrated 
on aligned fibers and had effect on controlling the tumor volume. 
To further test the tumor cell migration in another   in-vivo model of GBM the 
brain of green fluorescent protein (GFP) expressing transgenic mice, we have designed 
our brain implants such that the aligned electrospun nanofiber films become a pathway of 
migration for the GBM migration. In this context, two new implant designs were 
evaluated in this study. Once the implants are surgically fixed into mice brains, the tumor 
cells in the brain should align with the nanofiber films of the implants as demonstrated 
earlier.[14] The  strategy is similar to that is observed earlier in the rat model where tumor 
cells will  migrate along the nanofiber films from the tumor and to an apoptotic sink at 
the end of the films. At the apoptotic sink, the tumors cells could be destroyed by various 







CHAPTER 2: LITERATURE REVIEW 
Tumors in general can be benign or malignant, and in the case of brain tumors, 
the tumors can occur in different parts of the brain, and they may or may not be primary 
tumors. Benign tumors are clinically better manageable, while malignant tumors are 
generally more serious and are often a threat to life. Usually benign tumors can be 
surgically removed, and they seldom grow back, as opposed to malignant tumors, which 
are likely to grow rapidly and/or invade nearby healthy brain tissue. There are two types 
of brain tumors, primary and metastatic. A primary tumor can be defined as a tumor that 
has started in the brain while the metastatic tumor is a tumor that has spread to the brain 
from another part of the body.[1] 
Among the primary malignant tumors in adults, the most common is the 
Glioblastoma multiforme (GBM), which accounts for nearly 50% of reported malignant 
tumors. It was reported that the GBM accounts for approximately 70% of the 22, 000 
new cases of malignant primary brain tumors that are diagnosed in adults in the United 
States each year. Also, it was reported that the medial survival rate of patients diagnosed 
with GBM is at about one year, with tumor recurrence and progression inevitable in 
almost all cases.[2] Current literature has shown that there is a pressing need for a cure for 
this tumor as it remains resistant to current treatments despite advances in surgical 
techniques, neuroimaging, chemotherapy, and radiation.[3]  
Clinical observations suggest that these GBM tumors migrate as single cells, 
particularly along white matter tracts, despite the fact that white matter is an inhibitory 
substrate for neurite outgrowth and astrocyte migration.[4] The reasons for this 
phenomenon is currently not yet fully understood.[5] However, this phenomenon has been 
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a basis for many biomaterial-based models which have been created to mimic the white 
matter tracts to induce migration of GBM and other malignant brain tumors.  
Earlier work has shown that there have been many attempts to create the suitable 
biomaterial for evaluating tumor cell migration, and the most popular biomaterial for the 
past two decades has been the Matrigel.[6-8] Matrigel is a natural biomaterial from a 
mouse tumor extract that is popular, but bears little resemblance to the composition of the 
brain, being substantially different from normal brain tissue.[9] Hence, the search for the 
biomaterials that facilitate  tumor cell migration was ongoing until the introduction of 
electrospun nanofiber films that mimic white matter.   
Current literature shows that there have been many attempts to mimic white 
matter with electrospun nanofiber films, with many different parameters to create the 
optimum material for tumor migration.[10-12] This sudden surge in research  into nanofiber 
films indicates that researchers are looking into the GBM tumors migrating along white 
matter tracts; a phenomenon, which may lead to further studies and possibly treatment for 
GBM. As the anisotropic elongated structures and nanotopography accurately reflect the 
mechanical and structural cues present in the brain extracellular matrix (ECM) of the 
white matter tracts, many researchers have started to use electrospun nanofibers of 
polycaprolactone (PCL) with average diameters of  less than 1 µm to study GBM 
migration.[11, 12]  
As opposed to any form of topography  of PCL nanofibers or films with aligned 
topography was shown to provide structural advantage for promoting cell migration, 
where the alignment probably mimicked white matter tracts most accurately.[10] Among 
the different nanofiber models currently being used, the most promising model proposes 
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to use core-shell electrospun nanofibers to mimic white matter tract topography to 
examine the migration of malignant brain tumors.[12] Similar to what was used in the 




CHAPTER 3: MATERIALS AND METHODS 
SeeDB Optical Clearing Protocol 
 SeeDB is a water-based optical clearing agent, which clears fixed brain samples 
within three days, and it is especially ideal for GBM brain tumor quantification as it 
clears the membrane without quenching the fluorescent dyes in the brain.[15] Fructose, 
distilled water and α-thioglycerol were  used in the protocol, details of which can be 
found in  Appendix A.  
Electrospun Nanofiber Tumor Guidance Implants & Experimental Set-up 
Two different types of implants have been proposed, where the two implants were 
carefully designed for guiding tumor cell migration in mice brain. The aligned nanofibers 
in the implants were fabricated by electrospinning as indicated in the Appendix A.  
 
Figure 3-1. Silicone Implant on the left and a Conduit Implant on the right 
The aligned nanofibers were attached to the implants shown in Figure 3-1. The 
experiment was set-up such that there are four different conditions – Craniotomy, Smooth 
Conduit Implant, Aligned Conduit Implant and Aligned Silicone Tube Implant. The 
smooth conduit and the aligned conduit had the same implant design. The craniotomy 
served as the negative control for all conditions and the smooth conduit served as the 







CHAPTER 4: RESULTS 
SeeDB Optical Clearing of Mice Brain 
 
Figure 4-1: SeeDB cleared GBM tumor brain sample a, 1-mm-thick section imaged at 
a magnification of 10x b, another section imaged at 2x c, 3D image of the brain using z-
stack imaging by confocal microscopy. 
 
Initial testing for SeeDB optical clearing protocol on mice brain with GBM was 
done before data quantification. The optical clearing effects of SeeDB at various 
magnification is shown in Figure 4-1. The bright green fluorescent regions represent GFP 







Figure 4-2: Brain implants prior to quantification a, GBM tumor brain implanted with 
an aligned conduit implant b, SeeDB cleared brain with GBM tumor visible under 
fluorescent light c, silicone implant removed from a mice d, Removed silicone implant 
under fluorescent light, bottlenecking observed 
 
It was observed that the mice brain had merged with part of the aligned conduit 
implant, as illustrated in Figure 4-2a. The aligned conduit implant was closely attached 
with the mice brain at the region of insertion and where the aligned electrospun 
nanofibers had come in contact with  the tumor. For the silicone tube implant, 
bottlenecking of GBM tumors on the implant was observed. The sheer volume of tumor 
migration in the tube implant was observed to be much less than those of the aligned 





Figure 4-3: Representative image of GBM migration, aligned conduit implant vs 
smooth conduit implant scale bars at 500 μm a, cross section of the entire GBM tumor 
with aligned conduit implant visible to the left of the image b, cross section of the entire 
GBM tumor with smooth conduit implant – implant removed prior to imaging and 
quantification c, close up of image 4-3a, migration of GBM tumor towards the implant d, 
close up of image 4-3b, migration of GBM tumor towards where the implant 
 
 Representative images of GBM migration in aligned conduit implant and in 
smooth conduit implant can be seen in Figure 4-3. As shown in Figure 4-3a and 4-3c, the 
aligned conduit implant is present – the aligned conduit implant had attached firmly with 
the brain tissue, where removing the implant without significantly damaging the tissues 




Figure 4-4: Ratio of migrated GBM tumor to total tumor in smooth film conduit 
and aligned film conduit samples, n = 12 and α = 0.05, with student’s t-test Brain 
sections of a mouse implanted with the smooth film conduit and another with the aligned 
film conduit were evaluated. 12 sections of each mouse at similar sections of the brains 
were measured for total tumor size and total migrated tumor size. Error bars represent 
standard error of the mean. P-value of 2.01× 10-5 
 
 Random sections from similar region of the brain from a mouse implanted with a 
smooth film conduit and that from an aligned film conduit condition were imaged and 
quantified. Twelve sections were taken from each mouse and were measured for total 
tumor size and total migrated tumor size. It was found that the difference in the ratio of 
migrated tumor size to total tumor size was statistically significant, with the aligned film 






































CHAPTER 5: DISCUSSION 
SeeDB Optical Clearing Technique for Tumor Volume Quantification 
The SeeDB optical clearing of the brain with GBM made quantification of the 
volume of GBM much more efficiently. The optical clearing technique allowed brain 
sections up to 1mm to be quantified accurately and precisely. The entire brain volume of 
the mice was not used for this study. However, the SeeDB protocol should therefore, as 
described, be a useful technique to be adopted for all subsequent in-vivo study for GFP 
expressing brain tumor migration.  
Silicone Tube Implant 
The silicone tube implant was initially designed based on cerebral shunts that are 
already being used in hospitals. Clinical testing and FDA approvals are already done for 
these cerebral shunts, and since the silicone implants are slight design modifications from 
the cerebral shunts, the process of having the silicone implants ready for use in clinical 
settings should allow for expedited approval for clinical use in comparison to the conduit 
implant. However, with the experiment showing negative results for the current design, 
the silicone tube implant should be redesigned to produce effective cell migration from 
the tumor.  
The implant was observed to be inefficient in guiding the migration of GBM 
tumor from the brain to the apoptotic sink at the other end of the implant. With 
bottlenecking of the GBM tumor occurring at the opening close to edge of the implant 
where the tumor cells were supposed to have migrated through and up the tube, the GBM 
tumor cells were observed to have not been able to go through the small opening. This 
phenomenon of bottlenecking may be due to the fact that the openings were positioned 
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lateral to the direction of migration. It may also be due to the decrease in surface area as 
the GBM tumor cells had to go through the small opening of the tubes.  
Aligned Conduit Implant 
 From the experiment, it was determined that the ratio of tumor volume migrated 
to the total tumor for the aligned conduit implant was significantly higher statistically 
when compared to the smooth aligned implant. The results indicated that the aligned 
conduit implant does indeed guide the tumor through the conduit. It must however be 
noted that the volume of the migrated tumor is small compared to the total volume of the 
brain for both the aligned and smooth implant with migration ratios at 6.35% and 3.96%, 
respectively. An improvement in the study could be using a mouse model with a smaller 
volume of GBM to examine the effectiveness of the aligned implants at a more 
containable tumor volume.  
FutureInvestigation with stem cells 
There have been several documented cases where there were tumor recurrences 
after brain tumors were removed surgically, and this is another problem to be considered 
with this study of non-invasive treatment of brain tumor cells. The reasons behind tumor 
recurrences could be due to tumor not removed completely during surgery, but the 
principal reason is due to the tumor stem cells that are in the brain. Whether tumor stem 
cells also have the capacity to migrate via aligned films is still unknown and a further 
study regarding this is needed urgently. If the problem of not being able to remove tumor 
stem cells is not solved, the prospects of using the aforementioned implant designs are 
bleak. Hence an in-vitro study of tumor stem cells should be done, and if the ingredients 
to the nanofiber films need to be changed, it should be done so accordingly. 
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CHAPTER 6: CONCLUSION 
Novel designs of brain implants to induce GBM tumor migration in-vivo have 
been evaluated in this experiment. The ratio of tumor migrated to the total tumor in the 
brain was evaluated for the conduit implant, and it was found that the aligned conduit 
implant was able to induce GBM tumor migration. The silicone tube implant had design 
flaws which caused bottlenecking at the beginning of the implant – further design 
iterations of the implant are needed. The results found in this investigation show that it is 
certainly possible to design a brain implant that is able to remove GBM tumor non-
invasively, which indicate a promising future for brain tumor treatment.  
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APPENDIX A: MATERIALS AND METHODS 
 
PCL Nanofiber Protocol 
 
10%PCL:   4.5ml Hexafuoro-2-propanol (HFIP) 
  0.5ml Dimethyl formide (DMF) 
  500mg Polycaproluctone (PCL Beads) 
12%PCL:  4.5 ml HFIP 
  0.5ml DMF 
  600mg PCL Beads 
1. Wear nitrite gloves and work under the hood. 
2. Label glass vial and put in stirrer. 
3. Weigh the PCL beads. 
4. Put DMF into vial using a glass pipette. 
5. Add HFIP to DMF (will cause smoke) and start stirrer. 
6. Add the beads. 
7. Leave to mix overnight (takes >10 hrs for polymer to dissolve). 
*The thicker the concentration of the polymer the thicker the fibers. (12% PCL) 
 
 
Spinning the aligned nanofiber film 
1. Cut out aluminum sheet to appropriate size using the template. 
2. Spray and wipe the aluminum with EtOH and tape tightly around the metal rotary 
collector. 
3. With a 3ml syringe, take the needle from DCN solution and pump DCN to clean the 
needle. 
4. Remove the needle and draw up 1ml of 12% PCL solution using the syringe. 
5. Put needle back on and secure the syringe on the apparatus by putting the bar across the 
syringe and tightening the screw. 
6. Place the clamp 2/3 from the tip of the needle. 
7. Set the infusion rate on apparatus by clicking set infusion rate  1ml/hr enter. 
8. The distance from the tip of the needle to collection surface should be 8-10 cm. 
9. Check to see if PCL solution is coming out of the needle and wipe with tissue. 
10. Lower the safety cover, turn on the power, then turn on the voltage at 8-10 kilovolts. 
11. Spin for 20 minutes and check with a flashlight to see that there is only one thread being 
spun. 
12. If more than one thread, turn off the volt, then turn off power, stop the apparatus and 
wipe the needle. Turn on everything again. 
13. After 20 minutes carefully remove the aluminum from the collector by cutting the tape 
with a scalpel. 
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 10 ml Dichloromethane (DCM)  
 1g Polyethylene glycol (PEG) 
 1g Polycaprolactone (PCL) 
 Metal rod (diameter = 2.5 – 3.0 mm) 
 PCL nanofiber film  
Procedures 
1. Mix 1g of PEG, 1g of PCL beads in 10ml DCM solution. Use heat if necessary.  
2. Dip the metal rod vertically into the solution such that the solution caps the rod, and pull 
the rod out slowly.  
3. Spin the rod for 30 seconds, allowing the solution to dry on the rod.  
4. Repeat steps 2 and 3 four more times (5 dips total).  
5. Leave the rod with the solution drying vertical overnight.   
6. Carefully remove the solidified capped conduit from the rod.  
7. Place the conduit in a tube with DI water and leave it overnight on an overhead spinner.  
8. Remove the conduit and let it dry.  
9. Cut the conduits such that the height is 3mm with two triangular teeth (2mm added to the 
3mm height) on each side of the conduit.  
10. Paste the aligned PCL films onto the conduit.  
 
 
Silicone-tube Implant  
 
Materials 
 Silicone Tube (diameter 2 mm) 
 Pink Laboratory Wax Glue 
 PCL Nanofiber film 
Procedures 
1. Cut the silicone tube to lengths of about 10 cm each and fill one end with pink wax such 
that it fills up to 2mm from one end of the tube.  
2. Cut two holes right below where the pink wax ends on the tube such that the holes are 
facing each other.  
3. Put the nanofiber film into the tube via the open end and have it go around the two holes, 
covering and wrapping around the pink end.   
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SeeDB Optical Clearing Protocol 
 




1. Fix the sample in 4% PFA at 4oC with gentle shaking overnight. 
2. Wash the sample in PBS three times (10 min each). 
3. (optional step for fragile samples) Embed the sample in 1% agarose gel in PBS with 
desired orientation and then trim away extra portion to minimize the sample size. The 
surface of the sample should be close to the surface of agarose gel, because the working 
distance of commercially available objective lens is limited. Agarose embedding should 
not be used for large tissues, because agarose embedding reduces the penetration of 
SeeDB into the samples. 
4. Incubate the sample in~20 mL of 20% (w/v) fructose solution in 50 mL conical tube, and 
then place the conical tube on a tube rotator (~4 rpm) or a seesaw shaker (~17 rpm) for 4-
8 hours, respectively. The incubation time is from 4 to 8 hours. A small piece of sample 
(e.g., slices) requires less time for optical clearing. Incubation should be performed at 25-
37 C. 
5. Incubate the sample in 40 %( w/v) fructose for 4-8 hours as above. 
6. Incubate the sample in 60 %( w/v) fructose for 4-8 hours. 
7. Incubate the sample in 80 %( w/v) fructose for 12 hours. (Samples may no longer sink in 
80% or higher concentrations of fructose.) 
8. Incubate the sample in 100 %( w/v) fructose for 12 hours. 
9. Incubate the sample in ~20 mL SeeDB for 24 hours. The incubation time can be extended 
up to 48 hours. The transparency can be evaluated by eyes at this stage. If the sample is 
successfully cleared, the adult brain sample should look like amber under a light source. 
10. If the clarity is still not enough for imaging, we recommend:  
A. (In this optical clearing session) Incubate the sample in~20 mL SeeDB37 solution at 37 C (in 
an air incubator) with gentle rotation for 24 hours. 
B. (In the next optical clearing session) Trim away unnecessary portion of your sample to 
increase the penetration of fructose solution. 
C. (In the next optical clearing session) If the sample and fluorescent markers are heat resistant, 
try SeeDB37ht protocol. 
 Composition 
 Fructose Solvent α-thioglycerol 
20% w/v 4g 
Add distilled water to 20 mL  
100 µL 
40% w/v 8g 
60% w/v 12g 
80% w/v 16g 
100% w/v 20g 
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